Capecitabine
Esophageal Squamous Cell Carcinoma
Explore 64 assets in Esophageal Squamous Cell Carcinoma →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Chongqing University Cancer Hospital
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06055166CT.gov A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors | — | Unknown | — | — | — |
NCT04510818CT.gov Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2) | — | Unknown | — | — | — |
NCT03185988CT.gov Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Esophageal Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Capecitabine (this asset) | Chongqing University Cancer Hospital | P2 | B · 60 |
| Fluorouracilum | AstraZeneca | P3 | BB |
| Irinotecan | Taiho Oncology, Inc. | P2 | BB |
| Levofolinic Acid | Taiho Oncology, Inc. | P3 | BB |
| Oxaliplatin | Taiho Oncology, Inc. | P3 | B |
| Cetuximab | Hummingbird Bioscience | P2 | B |
| Pembrolizumab | GV20 Therapeutics | P3 | B |
| Cis-Diamminedichloroplatinum Ii | AstraZeneca | P3 | B |
| Lenvatinib | Merck Sharp & Dohme LLC | P3 | B |
+42 more in the Esophageal Squamous Cell Carcinoma cohort
Other indications for Capecitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Carcinoma | — | P4 | BBB · 73 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 72 |
| Colorectal Neoplasm | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Capecitabine in Esophageal Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/capecitabine-esophageal-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →